Literature DB >> 24790400

Breast cancer by the numbers.

.   

Abstract

The American Cancer Society estimates that 40,000 women will die from breast cancer this year. But thanks to steady progress in the war on cancer, millions of U.S. women with a history of the disease are alive today. Key statistics on survival rates, therapies in use, and treatment costs are provided.

Entities:  

Year:  2014        PMID： 24790400      PMCID： PMC4005124     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

1.  Deaths: final data for 2010.

Authors:  Sherry L Murphy; Jiaquan Xu; Kenneth D Kochanek
Journal:  Natl Vital Stat Rep       Date:  2013-05-08

2.  Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years.

Authors:  Masaaki Kawai; Kathleen E Malone; Mei-Tzu C Tang; Christopher I Li
Journal:  Cancer       Date:  2014-02-10       Impact factor: 6.860
  2 in total
  5 in total

1.  Intronic Variant of MUTYH Gene Exhibits A Strong Association with Early Onset of Breast Cancer Susceptibility in Indonesian Women Population.

Authors:  Sonar Soni Panigoro; Erlin Listiyaningsih; Ika Nurlaila; Bharuno Mahesworo; Alam Ahmad Hidayat; Arif Budiarto; Digdo Sudigyo; Dian Amirullah; Simon Simon; James Baurley; Bens Pardamean
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

2.  Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors.

Authors:  I P C Buzatto; A Ribeiro-Silva; J M Andrade; H H A Carrara; W A Silveira; D G Tiezzi
Journal:  Braz J Med Biol Res       Date:  2017-01-26       Impact factor: 2.590

3.  A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.

Authors:  Bora Lim; Rashmi K Murthy; Jangsoon Lee; Summer A Jackson; Toshiaki Iwase; Darren W Davis; Jie S Willey; Jimin Wu; Yu Shen; Debu Tripathy; Ricardo Alvarez; Nuhad K Ibrahim; Abenaa M Brewster; Carlos H Barcenas; Powel H Brown; Sharon H Giordano; Stacy L Moulder; Daniel J Booser; Jeffrey A Moscow; Richard Piekarz; Vicente Valero; Naoto T Ueno
Journal:  Br J Cancer       Date:  2019-05-17       Impact factor: 7.640

4.  Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells.

Authors:  Molly DiScala; Matthew S Najor; Timothy Yung; Deri Morgan; Abde M Abukhdeir; Melody A Cobleigh
Journal:  PLoS One       Date:  2020-06-11       Impact factor: 3.240

Review 5.  Dynamic Interactions of Transcription Factors and Enhancer Reprogramming in Cancer Progression.

Authors:  Emily Zboril; Hannah Yoo; Lizhen Chen; Zhijie Liu
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.